Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00900302 · ClinicalTrials.gov registry record
OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer
A clinical trial, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- 98
- Enrollment target
NCT00900302: Completed study, sponsored by OHSU Knight Cancer Institute.
NCT00900302 is a clinical trial that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 98 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00900302 has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
Study Summary
RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protein expression in the sentinel lymph nodes of patients with cancer.
Primary Outcome
The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2005-04 |
| Est. Completion | 2011-03 |
What the finished NCT00900302 record still lists
NCT00900302 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target.
The record links to 0 conditions, and to 4 interventions - of which protein expression analysis is the first listed.
NCT00900302 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00900302 about?
NCT00900302 is a clinical study titled "OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer". RATIONALE: Studying protein expression in sentinel lymph node tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future. PURPOSE: This laboratory study is evaluating OX-40 protei...
What is the current status of trial NCT00900302?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2005-04. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00900302?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE), immunohistochemistry staining method (OTHER).
Who is sponsoring clinical trial NCT00900302?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia